Respiratory symptoms and chronic bronchitis in people with and without HIV infection by Sabin, C A et al.
Respiratory symptoms and chronic bronchitis in people with 
and without HIV infection
Article  (Published Version)
http://sro.sussex.ac.uk
Sabin, C A, Kunisaki, K M, Bagkeris, E, Post, F A, Sachikonye, M, Boffito, M, Anderson, J, 
Mallon, P W G, Williams, I, Vera, J H, Johnson, M, Babalis, D and Winston, A (2020) Respiratory 
symptoms and chronic bronchitis in people with and without HIV infection. HIV Medicine. pp. 1-
11. ISSN 1464-2662 
This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/93780/
This document is made available in accordance with publisher policies and may differ from the 
published  version or from the version of record. If you wish to cite this item you are advised to 
consult the publisher’s version. Please see the URL above for details on accessing the published 
version. 
Copyright and reuse: 
Sussex Research Online is a digital repository of the research output of the University.
Copyright and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable, the material 
made available in SRO has been checked for eligibility before being made available. 
Copies of full text items generally can be reproduced, displayed or performed and given to third 
parties in any format or medium for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge, provided that the authors, title and full bibliographic 
details are credited, a hyperlink and/or URL is given for the original metadata page and the 
content is not changed in any way. 
Respiratory symptoms and chronic bronchitis in people with
and without HIV infection
CA Sabin 1 KM Kunisaki,2 E Bagkeris,1 FA Post ,3 M Sachikonye,4 M Boffito,5 J Anderson,6 PWG Mallon,7
I Williams,1 JH Vera ,8,9 M Johnson,10 D Babalis11 and A Winston 12
1Institute for Global Health, UCL, London, UK, 2Minneapolis Veterans Affairs Health Care System, and University of
Minnesota, Minneapolis, MN, USA, 3Caldecot Centre, King’s College Hospital, London, UK, 4UK Community Advisory
Board (UK-CAB), London, UK, 5St. Stephen’s Centre, Chelsea and Westminster Hospital, London, UK, 6Homerton
University Hospital, London, UK, 7HIV Molecular Research Group, School of Medicine, University College Dublin, Dublin,
Ireland, 8Elton John Centre, Brighton and Sussex University Hospital, Brighton, UK, 9Department of Global Health and
Infection, Brighton and Sussex Medical School, Brighton, UK, 10Ian Charleson Day Centre, Royal Free NHS Trust,
London, UK, 11Imperial Clinical Trials Unit, Imperial College London, London, UK and 12Department of Infectious
Disease, Imperial College London, London, UK
Objectives
High rates of respiratory symptoms and chronic bronchitis (CB) are reported in people with HIV
infection (PWH). We investigated the prevalence of respiratory symptoms and CB in PWH and
HIV-negative people in the Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY)
study.
Methods
Assessment of respiratory symptoms and CB was undertaken using the modified form of the St.
George’s Respiratory Questionnaire for chronic obstructive pulmonary disease (COPD). Univariate (v2
tests, Mann–Whitney U tests and Spearman’s rank correlation) and multivariable (linear and logistic
regression) analyses were performed to consider associations of respiratory symptoms with
demographic, lifestyle and HIV-related parameters, and with depressive symptoms and quality of life.
Results
Among the 619 participants, respiratory Symptom scores were higher in older and younger PWH
compared to older HIV-negative people, with median (interquartile range) scores of 17.7 (6.2, 39.5),
17.5 (0.9, 30.0) and 9.0 (0.9, 17.5), respectively (P = 0.0001); these differences remained significant
after confounder adjustment. Sixty-three participants (10.2%) met the criteria for CB [44 (14.0%)
older PWH, 14 (9.2%) younger PWH, and five (3.3%) older HIV-negative people; P = 0.002], with
these differences also remaining after adjustment for confounding variables, particularly smoking
status [older vs. younger PWH: odds ratio (OR) 4.48 (95% confidence interval (CI) 1.64, 12.30);
P = 0.004; older PWH vs. HIV-negative people: OR 4.53 (95% CI 1.12, 18.28); P = 0.03].
Respiratory symptoms and CB were both associated with greater depressive symptom scores and
poorer quality of life. No strong associations were reported between CB and immune function, HIV
RNA or previous diagnosis of any AIDS event.
Conclusions
Respiratory symptoms and CB are more common in PWH than in demographically and lifestyle-
similar HIV-negative people and are associated with poorer mental health and quality of life.
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measures, respiratory symptoms
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Introduction
With the increasing use of antiretroviral treatment (ART),
and resulting near-normal life expectancy in people with
HIV infection (PWH) in many parts of the world [1,2],
clinical focus in this group has shifted towards other
non-AIDS-related morbidities [3]. Chronic pulmonary dis-
ease and respiratory symptoms are reported to occur
more frequently among PWH than in the general popula-
tion [4,5], with rates of chronic obstructive pulmonary
disease (COPD) in the Strategic Timing of AntiRetroviral
Treatment (START) trial of 5.5–6.8% [6], although the
reasons for these higher rates remain unclear.
Chronic bronchitis (CB) affects approximately 10 mil-
lion people in the USA [7] and is associated with more
rapid lung function decline, increased risk of COPD exac-
erbations, reduced health-related quality of life [8], and
muscle weakness [9]. The primary risk factor for many
respiratory conditions, including CB, in the general popu-
lation is smoking [8], a behaviour that is prevalent in
PWH [10]. However, other factors known to cause or
exacerbate respiratory symptoms, including recreational
drug use, are also common in PWH [11], and, even
among those with controlled HIV viraemia on ART, pre-
viously diagnosed respiratory infections [including Pneu-
mocystis jirovecii pneumonia (PJP), bacterial pneumonia,
tuberculosis (TB) and cytomegalovirus (CMV) infection]
in those with prior immunosuppression may continue to
have a legacy effect. The identification of risk factors for
respiratory symptoms and CB in PWH is therefore crucial
if we are to effectively prevent and manage these condi-
tions.
Here we describe the prevalence of respiratory symp-
toms and CB among PWH and HIV-negative people in
the Pharmacokinetic and clinical Observations in PeoPle
over fiftY (POPPY) study, describe their associations with
patient-reported outcome measures, and investigate asso-
ciations with markers of HIV infection and immunosup-
pression.
Materials and methods
POPPY is a prospective cohort study, conducted at seven
clinical sites in the UK and one in Ireland, that aims to
investigate the impact of HIV on the development and
outcomes of comorbidities and pharmacotherapy among
older PWH [12]. Three subgroups are studied: older PWH
(≥ 50 years old), younger PWH (< 50 years old) and older
HIV-negative people (≥ 50 years old). Eligible PWH
acquired HIV through sexual transmission (either sex
between men or sex between men and women; those
acquiring HIV through other routes were excluded), were
cis-gender, and were of either white or black African eth-
nicity. The younger group of PWH were frequency-
matched to the older PWH on gender, ethnicity, sexual
orientation and participating clinic. HIV-negative partici-
pants were required to have a documented negative HIV
test; this group was frequency-matched to the older PWH
group on age, gender, ethnicity, sexual orientation and
geographical location (in/out of London). All participants
provided written informed consent and the protocol was
approved by the UK National Health Service Health
Research Authority and local ethics committees and/or
institutional review boards.
POPPY participants are seen for approximately annual
visits. At each visit, information is collected on socio-de-
mographics, pharmacotherapy, family history, medical
history, health care utilization and quality of life, with
additional information on specific clinical conditions col-
lected at some visits. Depressive symptoms are collected
through the Center for Epidemiological Studies Depres-
sion (CES-D) and the Patient Health Questionnaire-9
(PHQ-9) scales, with health-related quality of life being
assessed through the Short Form (36) Health Survey (SF-
36). The resulting POPPY data set is linked to the UK Col-
laborative HIV Cohort (UK sites [13]) and to the UCD ID
Cohort (Dublin [14]) for historic data on ART, prior AIDS
events, and longitudinal data on CD4+ and CD8+ T-cell
counts and HIV RNA.
Respiratory symptom assessment was introduced in
September 2016, mid-way through the cycle of the third
POPPY visit, using the short (40-question) version of the
St. George’s Respiratory Questionnaire for COPD (SGRQ-
C) [15]. To minimize the visit length, and as the SGRQ-C
was developed primarily for the assessment of respiratory
symptoms in COPD, we modified the use of the question-
naire. Whilst all participants completed the first part of
the SGRQ-C relating to the Symptoms component of the
scale, only those who reported symptoms that affected
them on several or most days of the week, who reported
one or more episodes of sudden shortness of breath or
who had only a few or no good days with few chest or
breathing problems were asked to complete the full
SGRQ-C for the Activity and Impacts components. We
also used the SGRQ-C symptom questions to determine
the presence of CB. Although CB is traditionally defined
as cough and sputum for at least 3 months per year for 2
consecutive years, the use of SGRQ symptom questions
has been shown to have good sensitivity (87%) and speci-
ficity (77%) for the traditional CB definition [16]. Partici-
pants were classified as having CB if they responded
“almost every day” or “most days a week” to the follow-
ing questions: “Over the last 4 weeks, I have coughed”
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and “Over the last 4 weeks, I have brought up phlegm
(sputum)”.
Statistical analysis
The scores for the Symptoms, Activity and Impacts com-
ponents of the SGRQ-C as well as the total score were
calculated as described in the study manual [15]. Missing
responses to items relating to the Symptoms component
were assumed to be negative, and individuals with miss-
ing data on more than one item for the Symptoms com-
ponent, more than three items for the Activity
component or more than five items for the Impacts com-
ponent were excluded from the calculation of these
scores. Scores were then adjusted to be comparable with
the scores from the full SGRQ, with a total possible score
ranging from 0 (perfect respiratory health) to 100 (worst
respiratory health) and an established minimal clinically
important difference (MCID) of four points for the total
score [17]; component scores do not have an established
MCID.
The distribution of the Symptoms component score
(completed in all participants) was compared across
groups defined by lifestyle and demographic factors using
Mann–Whitney U tests. Factors considered were the
POPPY study group (older PWH, younger PWH or older
HIV-negative), gender, age (stratified as < 40 or ≥ 40;
< 50 or ≥ 50; < 60 or ≥ 60; and < 70 or ≥ 70 years), eth-
nicity (white or black African), sexuality/mode of HIV
infection (sex between men or sex between men and
women), body mass index (BMI; five groups, defined by
the quintiles of the distribution), smoking status (current/
social smoker, ex-smoker or never smoker), recreational
drug use in the past 6 months and educational attain-
ment [low (none/lower school only/not known) or high
(higher school/university/other higher education)]. Multi-
ple linear regression was then used to investigate the
association between POPPY study group and the Symp-
toms component score after log10 transformation. Spear-
man’s correlation was used to determine associations
between the Symptoms component score and depressive
symptom scores (CES-D and PHQ-9) and each subscale of
the SF-36 questionnaire.
The proportions meeting the criteria for CB were com-
pared between subgroups, as defined above, using v2 tests
and univariable/multivariable logistic regression models
to determine independent associations between POPPY
study group and the prevalence of CB after adjusting for
potential confounders. Depressive symptom scores and
scores on each of the SF-36 subscales were summarized
separately for those who did and did not meet the criteria
for CB using medians and interquartile ranges (IQRs), and
were compared in the two groups using the Mann–Whit-
ney U test. Associations with HIV-related parameters
[current and nadir CD4 T-cell counts, duration of expo-
sure to immunosuppression (years with a CD4 count
< 200 cells/lL), current CD8 T-cell count, the current
CD4:CD8 T-cell ratio, current HIV RNA, and prior diagno-
sis of any AIDS-related events] were tested for signifi-
cance using v2 tests. All analyses were performed using
SAS v9.3 (SAS Institute Inc., Cary, NC).
Results
Of the 1377 POPPY participants, 619 completed a SGRQ-
C (315 older PWH, 152 younger PWH and 152 older HIV-
negative people). There were no major differences in the
characteristics of those attending for a visit who did and
did not complete an SGRQ-C, other than the clinical site
attended by participants, reflecting the staggered visit
timing across sites. Table 1 shows the characteristics of
participants with a completed SGRQ-C, stratified by study
group.
Respiratory symptoms
Respiratory symptoms were more frequently reported in
older and younger PWH compared to older HIV-negative
people (Table S1a). The median (IQR) Symptoms compo-
nent score was 17.7 (6.2, 39.5) in older PWH, 17.5 (0.9,
30.0) in younger PWH but only 9.0 (0.9, 17.5) in older
HIV-negative people (P = 0.0001). In total, 149 (47.3%)
older PWH, 56 (36.8%) younger PWH and 36 (23.7%)
older HIV-negative people reported symptoms and were
asked to complete the remainder of the SGRQ-C
(Table S1b). Median (IQR) Activity scores were 33.1 (13.6,
59.5), 20.4 (7.0, 39.7) and 13.7 (7.0, 26.8), respectively, in
the three groups (P = 0.003), whereas median (IQR)
Impacts scores were 10.5 (4.0, 24.8), 6.9 (2.2, 19.3) and
4.0 (2.2, 9.2), respectively (P = 0.009). Overall, in this
subgroup of participants reporting substantial symptoms,
the median (IQR) total SGRQ-C score was 23.3 (12.2,
38.5; n = 122), 18.2 (9.6, 28.0; n = 47) and 13.3 (7.6,
18.4; n = 34) in the three groups, respectively
(P = 0.002).
In addition to differences between PWH and HIV-nega-
tive people, unadjusted analyses showed that Symptoms
scores were higher in men (P = 0.0002), those of white
ethnicity (P = 0.09), those reporting sex between men
(P = 0.0009), current/social and ex-smokers (P = 0.0001),
those reporting recreational drug use in the past
6 months (P = 0.001) and those with lower educational
attainment (P = 0.001) (Table 2). In unadjusted analyses,
the mean log(Symptoms score) (LSS) was 0.13 [standard
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error (SE) 0.06] higher in older PWH (corresponding to a
34% higher value) when compared to younger PWH
(P = 0.05), and was 0.40 (SE 0.06) higher (151%) in older
PWH when compared to older HIV-negative people
(P = 0.0001). Of the lifestyle/demographic factors, only
gender, smoking status and educational attainment
remained significant in adjusted analyses. After adjust-
ment for these factors, the mean LSS in older PWH was
0.11 (SE 0.06) higher (29%) than in younger PWH
(P = 0.08) but was 0.34 (SE 0.06) higher (119%) than in
HIV-negative people (P = 0.0001).
There were strong correlations between the Symptoms
component score and both the CES-D and PHQ-9, as well
as each subscale of the SF-36 (Table 3) in the full cohort,
with similar associations seen in the subgroup of PWH
(data not shown). The median Symptoms component
score was higher in the 202 participants with a previously
reported chest problem than in the 417 without [27.2
(IQR 11.1, 47.3) and 11.1 (0.9, 21.7) in the two groups,
respectively; P = 0.0001].
The 467 PWH in the study had a median CD4 count of
667 (IQR 522, 883) cells/lL, a median nadir CD4 count
of 202 (IQR 98, 310) cells/lL (n = 465), a median CD8
count of 882 (IQR 652, 1160) cells/lL (n = 450) and a
median current CD4:CD8 T-cell ratio of 0.75 (IQR 0.56,
1.05) (n = 450). Participants had been exposed to
immunosuppression for a median of 0 (IQR 0, 0.5) years,
all were currently receiving combination antiretroviral
therapy (cART) and 424/465 (91.2%) had an HIV RNA
level ≤ 50 HIV-1 RNA copies/mL. Associations with HIV-
related factors (Table 4) were generally weak and/or
inconsistent.
Chronic bronchitis
Overall, 63 participants (10.2%) met the criteria for CB: 44
(14.0%) older PWH, 14 (9.2%) younger PWH and five
(3.3%) older HIV-negative people (P = 0.002; v2 test). The
prevalence of CB was higher in current and ex-smokers
than in social or never smokers (P = 0.0001) but did not
appear to differ by any other demographic or lifestyle fac-
tor (Table 2). In unadjusted logistic regression, the odds of
having CB were 4.77 times as high in older PWH [95% con-
fidence interval (CI) 1.85, 12.30; P = 0.001] and 2.98 times
as high in younger PWH (95% CI 1.05, 8.50; P = 0.04)
compared to older HIV-negative people (Fig. 1). These
increased risks were not reduced after adjustment for smok-
ing status alone [4.98 (95% CI 1.83, 13.57; P = 0.002) and
4.82 (95% CI 1.23, 18.92; P = 0.02), respectively] nor after
adjustment for all factors shown in Table 2 [4.48 (95% CI
1.64, 12.30; P = 0.004) and 4.53 (95% CI 1.12, 18.28;
P = 0.03), respectively], although CIs were wide (Fig. 1).
Those meeting the criteria for CB had more depressive
symptoms and lower scores on each of the SF-36 sub-
scales (Table 3). Thirty-seven (16.4%) of those with a pre-
viously reported chest problem met the criteria for CB
compared to only 26 (6.6%) of those without
(P = 0.0001; v2 test). As with the respiratory symptoms,
associations of CB with HIV-related factors (Table 4) were
generally weak and/or inconsistent.
Table 1 Characteristics of participants who provided respiratory data, stratified by Pharmacokinetic and clinical Observations in PeoPle over
fiftY (POPPY) study group
Study group
HIV-negative ≥ 50 yearsTotal PWH ≥ 50 years PWH < 50 years
Number 619 315 152 152
Gender [n (%)] Male 493 (79.6) 276 (87.6) 125 (82.2) 92 (60.5)
Female 126 (20.4) 39 (12.4) 27 (17.8) 60 (39.5)
Ethnicity [n (%)] White 536 (86.6) 275 (87.3) 124 (81.6) 137 (90.1)
Black African 83 (13.4) 40 (12.7) 28 (18.4) 15 (9.9)
Sexuality/mode MSM 435 (70.3) 252 (80.0) 112 (73.7) 71 (46.7)
of infection [n (%)] Heterosexual 184 (29.7) 63 (20.0) 40 (26.3) 81 (53.3)
Age (years) [median (IQR)] 54 (50, 60) 56 (53, 62) 42 (36, 47) 57 (53, 62)
Body mass index (kg/m2) [median (IQR)]‡ 25.7 (23.2, 28.6) 25.7 (23.5, 28.7) 24.7 (22.4, 27.7) 26.5 (23.8, 29.3)
Smoking status [n (%)]‡ Current 127 (20.5) 65 (20.6) 46 (30.3) 16 (10.5)
Ex-smoker 236 (38.1) 127 (40.3) 42 (27.6) 67 (44.1)
Never/unknown 256 (41.4) 123 (3.0) 64 (42.1) 69 (45.4)
Recreational drug use in No 463 (74.8) 244 (77.5) 92 (60.5) 127 (83.6)
past 6 months [n (%)] Yes 156 (25.2) 71 (22.5) 60 (39.5) 25 (16.5)
Education† [n (%)]‡ Low/unknown 165 (26.7) 92 (29.2) 35 (23.0) 38 (25.0)
High 454 (73.3) 223 (70.8) 117 (77.0) 114 (75.0)
IQR, interquartile range; PWH, people with HIV infection; MSM, men who have sex with men.
†Low: none/lower school only; high: higher school/university/other higher education.
‡Information was missing for the following numbers of participants: body mass index, n = 8; smoking status, n = 2; educational level, n = 22.
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Discussion
In this large multicentre cohort of PWH, using a well-
established and validated respiratory symptom question-
naire, we found that respiratory symptoms and CB were
more common and had greater reported impact in PWH
than in demographically and lifestyle-similar HIV-nega-
tive people. These symptoms, which were associated with
greater depressive symptoms and poorer quality of life,
continued to be more common in PWH even after adjust-
ment for known confounders. Importantly, and in con-
trast to our expectations, respiratory symptoms and CB
Table 2 Median Symptoms scores and prevalence of chronic bronchitis in groups defined by demographic and lifestyle factors, and P-values
from unadjusted analyses
Median (IQR)
Symptoms score P-value
Chronic bronchitis
[n (%)] P-value
Total 15.0 (0.9, 31.2) 63 (10.2)
POPPY study group PWH ≥ 50 years 17.7 (6.2, 39.5) 0.0001 44 (14.0) 0.002
PWH < 50 years 17.5 (0.9, 30.0) 14 (9.2)
HIV-negative ≥ 50 years 9.0 (0.9, 17.5) 5 (3.3)
Gender Male 17.5 (5.9, 33.4) 0.0002 55 (11.2) 0.15
Female 11.1 (0.9, 17.9) 8 (6.4)
Age < 40 years 14.0 (11.1, 33.4) 0.96 6 (12.0) 0.40
≥ 40, < 50 years 17.5 (0.9, 27.4) 8 (7.8)
≥ 50, < 60 years 14.3 (0.9, 33.1) 27 (9.2)
≥ 60, < 70 years 14.4 (5.9, 28.5) 17 (11.6)
≥ 70 years 14.1 (0.9, 47.1) 5 (20.0)
Ethnicity White 17.5 (5.9, 31.9) 0.09 57 (10.6) 0.45
Black African 11.1 (0.9, 24.2) 6 (7.2)
Sexuality/mode of infection MSM 17.5 (5.9, 33.8) 0.0009 49 (11.3) 0.22
Heterosexual 11.1 (0.9, 24.2) 14 (7.6)
BMI < 22.8 kg/m2 17.5 (0.9, 38.2) 0.62 14 (11.6) 0.13
≥ 22.8, < 24.8 kg/m2 12.7 (0.9, 24.2) 7 (5.7)
≥ 24.8, < 26.9 kg/m2 12.4 (0.9, 33.1) 19 (15.5)
≥ 26.9, < 29.5 kg/m2 17.3 (6.2, 30.0) 13 (10.7)
≥ 29.5 kg/m2 17.5 (5.9, 32.8) 10 (8.1)
Smoking status Current/social 23.8 (11.1, 45.0) 0.0001 27 (21.3) 0.0001
Ex-smoker 17.5 (6.0, 33.3) 27 (11.4)
Never/unknown 11.1 (0.9, 21.7) 9 (3.5)
Recreational drug use in past 6 months No 11.1 (0.9, 27.8) 0.001 42 (9.1) 0.16
Yes 18.6 (11.1, 37.4) 21 (13.5)
Educational level† Low/unknown 17.9 (6.0, 45.4) 0.001 20 (12.1) 0.42
High 11.1 (0.9, 27.0) 43 (9.5)
BMI, body mass index; IQR, interquartile range; MSM, men who have sex with men; POPPY, Pharmacokinetic and Clinical Observations in People over
Fifty; PWH, people with HIV infection.
† Low: none/lower school only; high: higher school/university/other higher education.
Table 3 Associations of the Symptoms score and the prevalence of chronic bronchitis and patient-reported outcomes [Center for Epidemio-
logical Studies Depression (CES-D), Patient Health Questionnaire-9 (PHQ-9) and Short Form (36) Health Survey (SF-36) scales], and P-values
from unadjusted analyses
Measure
Symptoms score:
Spearman’s r P-value
No chronic bronchitis
Median (IQR)
Chronic bronchitis
Median (IQR) P-value
Depressive symptom score
CES-D 0.41 0.0001 7 (3, 15) 16 (7, 28) 0.0001
PHQ-9 0.41 0.0001 2 (0, 6) 9 (2, 13) 0.0001
SF-36 subscale
Physical functioning 0.39 0.0001 95 (80, 100) 80 (40, 95) 0.0001
Physical limitations 0.35 0.0001 100 (75, 100) 50 (0, 100) 0.0001
Emotional limitations 0.31 0.0001 100 (67, 100) 67 (0, 100) 0.0005
Energy/fatigue 0.42 0.0001 65 (50, 80) 50 (30, 65) 0.0001
Emotional wellbeing 0.34 0.0001 80 (64, 92) 68 (48, 80) 0.0001
Social functioning 0.38 0.0001 90 (68, 100) 68 (43, 90) 0.0001
Pain 0.35 0.0001 80 (58, 100) 68 (32, 90) 0.0001
General health 0.45 0.0001 70 (55, 85) 55 (30, 75) 0.0003
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were not strongly associated with measures of immune
dysfunction, suggesting that the higher rate seen in PWH
may reflect unmeasured lifestyle, demographic or labora-
tory factors rather than specific disease effects or legacy
effects of HIV disease per se.
PWH have been reported to have poorer respiratory
health than the general population, although the reasons
for this remain unclear. In a large systematic review and
meta-analysis, Brown et al. [4] reported that, compared to
HIV-negative people, PWH were more likely to have a
cough in populations without access to ART. However, no
strong association between HIV infection and the pres-
ence of a cough was seen among populations in
resource-rich settings with access to ART, suggesting that
HIV may play a direct role in the development of respira-
tory symptoms. Using the SGRQ, Leung et al. [18]
reported associations of respiratory health status with low
CD4 count, systemic inflammation and forced expiratory
volume among men with HIV infection in Canada; how-
ever, no assessment was made of associations with respi-
ratory symptoms themselves, or with CB. Similarly,
Kunisaki et al. reported worse SGRQ Symptoms scores in
men with HIV infection compared to men without HIV
infection. However, they did not investigate risk factors
for having worse symptoms, the impact of symptoms on
quality of life, or the presence of CB [19]. A higher
Table 4 Median Symptoms score and prevalence of chronic bronchitis in groups defined by HIV-related factors, and P-values from unadjusted
analyses
n (% of total group
of PWH)
Median (IQR)
Symptoms score P-value
Chronic bronchitis
n (% of those in
each group) P-value
Number 467 (100.0) 58 (12.4)
Current CD4 count < 200 cells/lL 8 (1.7) 33.8 (8.0, 56.1) 0.50 0 (-) 0.07
≥ 200, < 350 cells/lL 30 (6.4) 24.2 (11.1, 50.8) 5 (16.7)
≥ 350, < 500 cells/lL 73 (15.6) 17.9 (6.2, 33.4) 7 (9.6)
≥ 500, < 750 cells/lL 184 (39.4) 17.5 (6.2, 30.5) 16 (8.7)
≥ 750 cells/lL 172 (36.8) 17.5 (5.9, 42.2) 30 (17.4)
Nadir CD4 count < 200 cells/lL 227 (48.6) 17.5 (9.2, 42.2) 0.35 29 (12.8) 0.01
≥ 200, < 350 cells/lL 144 (31.1) 17.5 (0.9, 31.0) 13 (9.0)
≥ 350, < 500 cells/lL 61 (13.3) 19.3 (6.2, 36.2) 6 (9.8)
≥ 500, < 750 cells/lL 26 (5.4) 17.5 (0.9, 33.1) 7 (26.9)
≥ 750 cells/lL 7 (1.3) 17.5 (11.1, 57.0) 3 (42.9)
Exposure to immunosuppression† None 245 (52.5) 17.5 (0.9, 33.1) 0.07 29 (11.8) 0.87
> 0–2 years 158 (33.8) 17.5 (7.7, 36.6) 20 (12.7)
> 2–4 years 26 (5.6) 15.0 (7.3, 45.4) 3 (11.5)
> 4 years 36 (7.7) 24.2 (14.7, 52.6) 6 (16.7)
Current CD8 count ≤ 600 cells/lL 90 (20.0) 17.5 (6.2, 36.6) 0.81 12 (13.3) 0.82
> 600, ≤ 800 cells/lL 93 (20.7) 17.5 (0.9, 37.0) 10 (10.8)
> 800, ≤ 1000 cells/lL 91 (20.2) 11.1 (5.9, 36.6) 13 (14.3)
> 1000, ≤ 1200 cells/lL 70 (15.6) 17.5 (11.1, 28.1) 7 (10.0)
> 1200 cells/lL 106 (23.6) 17.5 (5.9, 42.5) 16 (15.1)
Current CD4:CD8 ratio ≤ 0.4 53 (11.8) 17.3 (0.9, 24.2) 0.18 6 (11.3) 0.20
> 0.4, ≤ 0.6 91 (20.2) 17.5 (5.9, 34.8) 11 (12.1)
> 0.6, ≤ 0.8 110 (24.4) 14.4 (6.2, 27.0) 8 (7.3)
> 0.8, ≤ 1.0 69 (15.3) 11.1 (0.9, 33.4) 12 (17.4)
> 1.0 127 (28.2) 23.5 (7.7, 50.7) 21 (16.5)
HIV RNA < 50 copies/mL No 41 (8.8) 18.2 (11.1, 27.4) 0.92 4 (9.8) 0.76
Yes 424 (91.2) 17.5 (6.2, 36.3) 54 (12.7)
Ever had:
Any AIDS event No 339 (72.6) 17.5 (6.2, 33.1) 0.19 41 (12.1) 0.73
Yes 128 (27.4) 23.6 (5.9, 46.0) 17 (13.3)
Cytomegalovirus disease No 457 (97.9) 17.5 (6.2, 35.2) 0.48 57 (12.5) 1.00
Yes 10 (2.1) 24.2 (5.9, 50.6) 1 (10.0)
Pneumocystis jiroveci pneumonia No 425 (91.0) 17.5 (6.2, 35.0) 0.74 54 (12.7) 0.73
Yes 42 (9.0) 24.2 (5.9, 50.6) 4 (9.5)
Tuberculosis No 433 (92.7) 17.5 (6.2, 35.0) 0.70 52 (12.0) 0.49
Yes 34 (7.3) 17.5 (5.9, 45.4) 6 (17.7)
Kaposi’s sarcoma No 439 (94.0) 17.5 (5.9, 33.4) 0.05 54 (12.3) 0.99
Yes 28 (6.0) 25.7 (11.1, 53.3) 4 (14.3)
Other AIDS event No 424 (90.8) 17.5 (5.9, 33.4) 0.09 51 (12.0) 0.57
Yes 43 (9.2) 24.2 (11.1, 47.0) 7 (16.3)
IQR, interquartile range; PWH, people with HIV infection.
†Duration of time spent with a CD4 count < 200 cells/lL.
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prevalence of COPD has also been reported among PWH
than among HIV-negative controls, particularly among
those with a detectable HIV viral load [20] or low CD4
count [21,22]. Whilst we did not find associations
between respiratory symptoms and measures of HIV sta-
tus, we should note that very few PWH (8.1% of our
cohort) had CD4 counts < 350 cells/lL, prior exposure to
immunosuppression was uncommon and all PWH were
on ART, restricting our ability to assess the effects of
these factors.
As noted above, adjustment for socio-demographic and
lifestyle factors, including smoking, did not substantially
attenuate the associations with HIV infection in our
study. It is possible that other confounders may be pre-
sent which we have been unable to control for in analy-
ses, including factors such as indoor air quality, second-
hand smoke, occupational exposures, and exercise. Alter-
natively, HIV may exert an effect through novel, as yet
undetermined, HIV-specific mechanistic pathways that
are distinct from traditional measures of HIV control
(CD4 count and HIV RNA). For example, recently pub-
lished studies have suggested that lung disease in PWH
could be related to factors such as a potential latent lung
HIV reservoir, persistent viral protein production (e.g. Nef
and Tat), oxidative stress, and alterations in the respira-
tory microbiome [23-27].
Although respiratory symptoms in the general popula-
tion are associated with negative outcomes, including
cardiovascular comorbidity, hospitalization and mortality
[28,29], similar studies among PWH are lacking. Some
studies have considered associations between lung func-
tion and outcomes in PWH, reporting associations of
airflow obstruction, impaired diffusing capacity and
emphysema with mortality [30,31] and slower gait speed
[32], the latter suggesting an association with frailty as
also reported in the general population [9]. Whilst lung
function is only moderately correlated with respiratory
symptoms, these findings do suggest the potential for res-
piratory symptoms to impact on clinical outcomes, in
addition to the strong associations with depressive symp-
toms and quality of life seen in our study. Although res-
piratory symptoms have been reported to have an impact
on quality of life in the general population [33,34], there
are few published data on their associations with mental
health outcomes in PWH. Although a negative impact of
respiratory symptoms on mental health would be hypoth-
esized, we cannot rule out the possibility that poor men-
tal health may result in behaviours (e.g. increased
frequency of smoking or recreational drug use, decreased
physical activity and increased use of polypharmacy with
associated side effects) that themselves may increase the
risk of respiratory symptoms and/or CB.
We confirmed a strong association between smoking
and CB as in the general population [8,35], with no evi-
dence that this association differed between PWH and
HIV-negative people. Whilst it is known that smoking is
associated with both higher COPD risk [20-22] and accel-
erated lung function decline [36] among PWH, the contri-
bution of smoking to CB among PWH remains unclear.
Whilst the importance of cigarette smoking cessation for
the wider health of PWH has been widely documented
[11,37-39], reports of CB in nonsmokers in the general
population suggest the presence of other environmental,
occupational and genetic risk factors [8].
Fig. 1 Results from logistic regression analyses (odds ratios with 95% confidence intervals) for the association between Pharmacokinetic and
clinical Observations in PeoPle over fiftY (POPPY) study group and chronic bronchitis, before and after adjustment for (a) smoking and (b)
smoking and all factors listed in Table 2.
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Previous analyses of the original version of the SGRQ
have demonstrated mean symptom scores of 7.63 (male)/
6.49 (female) in healthy individuals compared to 22.55
(male)/12.43 (female) in patients with COPD and 32.82
(male)/26.34 (female) in patients with asthma [40], pro-
viding some indication of the expected values in different
populations. The magnitude of the difference in Symp-
toms score between PWH and HIV-negative people in our
study (10 points) suggests that a targeted assessment of
respiratory symptoms in PWH might have high yield,
particularly in older PWH who commonly reported respi-
ratory symptoms. Although our study did not include a
formal clinical assessment of respiratory symptoms, and
we did not formally assess respiratory function using
lung function tests (e.g. spirometry and tests measuring
the diffusing capacity of carbon monoxide), which would
have facilitated the diagnosis of underlying clinical con-
ditions, our Symptoms score is associated with estab-
lished risk factors for respiratory symptoms (e.g. smoking
and male gender) and with a self-reported history of
chest problems, suggesting that it is a valid marker of
respiratory symptoms in this group.
The adaptation of the SGRQ for the diagnosis of CB
[16] has been reported to have good diagnostic perfor-
mance when assessed against the classic CB definition
(chronic cough and sputum production for 3 months a
year for 2 consecutive years). However, this SGRQ-based
definition may identify a higher number of people with
CB than the classic definition. Kim et al. assessed the
presence of CB using both definitions in a cohort of 4513
current and former smokers and found that 26.1% met
the traditional CB definition, while 39.9% met the SGRQ-
based definition [16]. Thus, our findings may not be
directly comparable to studies using the traditional CB
definition. We are not aware of any previous data com-
paring CB prevalence in those with and without HIV
infection. Our data suggest that smoking does not explain
the higher CB prevalence in PWH, so other HIV-related
factors may play a role. Despite this, our prevalence of
CB was low, particularly in the HIV-negative group (pos-
sibly because of the low rate of cigarette smoking in the
cohort overall compared to some other studies), and thus
the power of our study to detect associations, particularly
with HIV-related parameters, may be reduced.
Our study benefits from a large sample of PWH which
is broadly representative of older PWH in Western Euro-
pean settings, a population with high levels of viral sup-
pression. As such, our sample is predominantly made up
of white MSM, limiting our ability to accurately report
the prevalence of CB and respiratory symptoms in women
or those of black and minority ethnic groups. In contrast
to earlier studies, our study also benefits from the
inclusion of appropriately selected HIV-negative people
with similar characteristics to the older PWH in the study,
allowing us to investigate the role of HIV infection in the
development of respiratory symptoms. However, associa-
tions that we can draw regarding causality are limited
and we cannot rule out the possibility of unmeasured
confounding. Furthermore, as items related to Activity
and Impacts were only collected in the subgroup of par-
ticipants who reported substantial symptoms, our findings
relating to these components (and the total score) are not
directly comparable to findings from other studies. Whilst
the POPPY study captures information on current and
past smoking, more detailed information on tobacco
exposure (e.g. pack-years) or on smoking alternatives
(e.g. vaping) may have provided additional ability to
adjust for this confounding factor. Finally, it is possible
that additional measures (e.g. the diffusing capacity of
carbon monoxide, exhaled nitric oxide, or chest/cardiac
computed tomography imaging) may provide additional
information about the aetiology of respiratory conditions
in this population.
Conclusions
In conclusion, respiratory symptoms and CB were more
commonly reported in PWH than in demographically and
lifestyle-similar HIV-negative people and were associated
strongly with mental health and quality of life. The iden-
tification and management of risk factors for these condi-
tions are essential if we are to ensure that PWH
experience optimal health-related outcomes.
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